ImmunityBio rises after Saudi nod for Anktiva (IBRX:NASDAQ)

ImmunityBio (IBRX) shares added ~12% in the premarket on Wednesday after the Saudi Food and Drug Authority approved its best-selling immunotherapy, Anktiva, for certain patients with bladder cancer. According to the San Diego, California-based biotech, the SFDA’s approval allows the company to ...